Zacks Research has upgraded Cardinal Health (NYSE:CAH) to a “strong-buy” rating, citing recent positive quarterly results, a confirmed dividend, and increased price targets from other analysts. The company reported $2.63 EPS, topping consensus estimates, with revenue up 18.8%. Institutional investors own a significant portion of its stock, and the consensus price target from analysts is $245.19.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Cardinal Health (NYSE:CAH) Upgraded by Zacks Research to Strong-Buy Rating
Zacks Research has upgraded Cardinal Health (NYSE:CAH) to a “strong-buy” rating, citing recent positive quarterly results, a confirmed dividend, and increased price targets from other analysts. The company reported $2.63 EPS, topping consensus estimates, with revenue up 18.8%. Institutional investors own a significant portion of its stock, and the consensus price target from analysts is $245.19.